在接受保乳手术联合放疗治疗的 DCIS 患者中，HER-2 过表达与同侧乳腺肿瘤复发增加无关。

HER-2 overexpression is not associated with increased ipsilateral breast tumor recurrence in DCIS treated with breast-conserving surgery followed by radiotherapy.

机构信息

Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 135-710, Republic of Korea.

出版信息

Breast. 2013 Oct;22(5):894-7. doi: 10.1016/j.breast.2013.04.001. Epub 2013 May 3.

DOI:10.1016/j.breast.2013.04.001

PMID:23643805

Abstract

BACKGROUND

We evaluated the clinical implications of human epidermal growth factor receptor (HER)-2 overexpression after adjuvant radiotherapy (RT) for ductal carcinoma in situ (DCIS).

METHODS

We reviewed 215 patients with DCIS who underwent breast-conserving surgery followed by RT. The association between HER-2 overexpression and ipsilateral breast tumor recurrence (IBTR) was evaluated.

RESULTS

HER-2 overexpression was associated with comedo-type architecture, high nuclear grade, and negative hormonal receptors. The median follow-up duration was 75 months. Sixteen patients experienced IBTR; seven as DCIS recurrence and nine as invasive recurrence. The IBTR rate was 11.4% at 10 years. There was no significant difference in IBTR according to HER-2 expression (P = 0.1764), neither in invasive nor DCIS recurrence. Time to recurrence was shorter in HER-2 positive tumors (P = 0.0697).

CONCLUSION

Adjuvant RT seems to counteract the negative effect of HER-2 overexpression in DCIS, while time to recurrence was relatively shorter.

摘要

背景

我们评估了人表皮生长因子受体（HER）-2 过表达在导管原位癌（DCIS）辅助放疗（RT）后的临床意义。

方法

我们回顾了 215 例接受保乳手术加 RT 的 DCIS 患者。评估了 HER-2 过表达与同侧乳房肿瘤复发（IBTR）之间的关系。

结果

HER-2 过表达与粉刺型结构、高核级和阴性激素受体有关。中位随访时间为 75 个月。16 例患者发生 IBTR；7 例为 DCIS 复发，9 例为浸润性复发。10 年时的 IBTR 率为 11.4%。HER-2 表达与 IBTR 无关（P = 0.1764），无论是浸润性复发还是 DCIS 复发。HER-2 阳性肿瘤的复发时间较短（P = 0.0697）。